221 related articles for article (PubMed ID: 26083990)
1. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
[TBL] [Abstract][Full Text] [Related]
2. Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Li MP; Xiong Y; Xu A; Zhou JP; Tang J; Zhang ZL; Zhou HH; Zhang W; Chen XP
Int J Hematol; 2014 Mar; 99(3):263-71. PubMed ID: 24474638
[TBL] [Abstract][Full Text] [Related]
3. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
4. Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor.
Hobl EL; Derhaschnig U; Firbas C; Schoergenhofer C; Schwameis M; Jilma B
Eur J Clin Invest; 2013 Dec; 43(12):1258-61. PubMed ID: 24112116
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.
Liu S; Xue L; Shi X; Sun Z; Zhu Z; Zhang X; Tian X
Eur J Clin Pharmacol; 2018 Jun; 74(6):745-754. PubMed ID: 29442148
[TBL] [Abstract][Full Text] [Related]
6. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
7. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
[TBL] [Abstract][Full Text] [Related]
8. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
9. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population.
Kim KA; Song WG; Lee HM; Joo HJ; Park JY
Thromb Res; 2013 Aug; 132(2):221-6. PubMed ID: 23849096
[TBL] [Abstract][Full Text] [Related]
10. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
[TBL] [Abstract][Full Text] [Related]
11. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Scharbert G; Wetzel L; Schrottmaier WC; Kral JB; Weber T; Assinger A
Transfusion; 2015 Jun; 55(6):1320-6. PubMed ID: 25641006
[TBL] [Abstract][Full Text] [Related]
12. Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects.
Oestreich JH; Steinhubl SR; Ferraris SP; Loftin CD; Akers WS
J Thromb Thrombolysis; 2014 Oct; 38(3):372-9. PubMed ID: 24510678
[TBL] [Abstract][Full Text] [Related]
13. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H
Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
17. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.
Fontana P; Dupont A; Gandrille S; Bachelot-Loza C; Reny JL; Aiach M; Gaussem P
Circulation; 2003 Aug; 108(8):989-95. PubMed ID: 12912815
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor inverse agonist activity at the P2Y
Khalil J; Dimofte T; Roberts T; Keith M; Amaradasa K; Hindle MS; Bancroft S; Hutchinson JL; Naseem K; Johnson T; Mundell SJ
Br J Pharmacol; 2024 Jan; 181(1):21-35. PubMed ID: 37530222
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
[TBL] [Abstract][Full Text] [Related]
20. Platelet inhibition by P2Y
Shih CC; Chan MV; Kirkby NS; Vojnovic I; Mitchell JA; Armstrong PC; Warner TD
Br J Pharmacol; 2021 Dec; 178(23):4758-4771. PubMed ID: 34383973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
